The largest pharmaceutical company in India, Cipla Limited, released its financial results on January 25 for the third quarter that ended on December 31, 2022 (Q3FY23).
For the quarter, the business declared a consolidated profit after tax (PAT) of Rs 801 crore, up 9.9% from the Rs 729 crore reported for the same period last year. It had recorded a profit of Rs 789 crore for the three months ending in September 22.
Consolidated revenue increased Y-o-Y by 6.0 percent to Rs 5,801 crore from Rs 5,479 crore in the same quarter of 2021. 5.829 billion rupees were earned during the second quarter of FY23.
The amount of earnings before interest, depreciation, tax, and amortisation (EBITDA) was Rs 1,408 crore, up 13.2 percent from the Rs 1,243 crore recorded in the previous year. On a sequential basis, it increased by 8.1 percent from the previous quarter’s Rs 1,302 crore.
